{"id":62673,"date":"2026-02-19T19:06:04","date_gmt":"2026-02-19T18:06:04","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/animate-biosciences-reports-preclinical-data-showing-dramatic-reduction-in-cardiac-scarring-and-near-doubling-of-heart-function-after-experimental-heart-attack\/"},"modified":"2026-02-19T19:06:04","modified_gmt":"2026-02-19T18:06:04","slug":"animate-biosciences-reports-preclinical-data-showing-dramatic-reduction-in-cardiac-scarring-and-near-doubling-of-heart-function-after-experimental-heart-attack","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/animate-biosciences-reports-preclinical-data-showing-dramatic-reduction-in-cardiac-scarring-and-near-doubling-of-heart-function-after-experimental-heart-attack\/","title":{"rendered":"Animate Biosciences Reports Preclinical Data Showing Dramatic Reduction in Cardiac Scarring and Near-Doubling of Heart Function After Experimental Heart Attack"},"content":{"rendered":"
\n

\nSingle-dose designed peptide drives structural and functional cardiac repair in a mouse myocardial infarction model<\/i><\/p>\n

SAN FRANCISCO–(BUSINESS WIRE)–Animate Biosciences<\/a>, a biotechnology company focused on designing innovative peptide therapeutics, today announces positive preclinical results demonstrating that its lead therapeutic peptide, MBb32, produced a significant reduction in cardiac scar tissue (infarct) and subsequent recovery of heart function in a mouse model of severe myocardial injury.<\/p>\n

<\/a>
<\/a><\/p>\n

\nHeart disease is the leading cause of death in the United States, accounting for a significant portion of annual mortality. In addition, tens of millions of Americans live with cardiovascular disease, and projections suggest that the prevalence of cardiovascular conditions will continue to rise in the coming decades. While current therapies help manage symptoms and slow disease progression after heart attack, few treatments directly reverse the structural damage caused by ischemic injury.<\/p>\n

\nThe study used a reliable left anterior descending (LAD) coronary artery ligation model that replicates key features of human heart attack and post-infarct remodeling. Following induction of myocardial infarction, animals received a single low dose injection of MBb32. Infarct size and cardiac performance were later quantified using advanced cardiac MRI acquisition and novel cellular contrast agent.<\/p>\n

\nTreatment with MBb32 resulted in significant 64% reduction in infarct burden, with scar size decreasing from 44% in untreated controls to 16% in peptide-treated animals (p<0.05). In parallel, MBb32 produced significant 90% improvement in cardiac function, with left ventricular ejection fraction increasing from 19% to 36% (p<0.05). The combination of large scar reduction and functional recovery is challenging in murine LAD infarction studies. These findings suggest physiologically meaningful tissue repair after severe injury.<\/p>\n

\n\u201cThese results demonstrate that our peptides can drive both structural and functional recovery following major cardiac injury,\u201d said Peter Licari, CEO and co-founder of Animate Biosciences. \u201cSeeing this magnitude of scar shrinkage alongside restoration of heart performance supports the reparative potential of our platform and expands our opportunity in cardiac disease.\u201d<\/p>\n

\nThe work was conducted by the Cardiovascular Stem Cell (Yang) Laboratory at Stanford. The model was intentionally designed to conduct a highly rigorous test of tissue rescue following major ischemic injury. The observed effects indicate an effective inhibition of pathological scar formation and meaningful restoration of cardiac pump function.<\/p>\n

\nPrior in vivo studies have shown that Animate peptides deliver powerful anti-fibrotic and regenerative effects across multiple organ systems. Combined with the new cardiac data, these results highlight the broad therapeutic potential of Animate\u2019s platform to repair damaged tissue and treat fibrosis systemically.<\/p>\n

\nAnimate Biosciences is developing a pipeline of AI-designed peptides targeting inflammation and fibrosis across multiple organs, including the lung, heart, liver, and skin. The company is advancing MBb32 and additional candidates toward IND-enabling studies as part of a broader strategy to create disease-modifying therapies that address the biological drivers of tissue degeneration. For more information, visit animate.bio<\/a>.<\/p>\n

\nAbout Animate Biosciences<\/span><\/b><\/p>\n

\nAnimate Biosciences is a biotechnology company developing first-of-its-kind peptide therapeutics to stop inflammatory and fibrotic disease. Powered by its proprietary AnimateIQ\u2122 platform, the company combines breakthroughs in biological data processing, generative AI and rapid peptide synthesis to design novel therapies. By leveraging the untapped biology of nature\u2019s best regenerators, the company aims to transform how inflammation and fibrosis are treated across organ systems, make advanced therapeutics accessible and deliver a future where life-altering or life-ending inflammatory and fibrotic disease is no longer inevitable. For more information, visit animate.bio<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia Contact:
\n
Carly Kuikman
\n
carly@cskpublicrelations.com<\/a>
(978) 604 – 0904<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Single-dose designed peptide drives structural and functional cardiac repair in a mouse myocardial infarction model SAN FRANCISCO–(BUSINESS WIRE)–Animate Biosciences, a biotechnology company focused on designing innovative peptide therapeutics, today announces positive preclinical results demonstrating that its lead therapeutic peptide, MBb32, produced a significant reduction in cardiac scar tissue (infarct) and subsequent recovery of heart function … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62673","6":"format-standard","7":"category-industry"},"yoast_head":"\nAnimate Biosciences Reports Preclinical Data Showing Dramatic Reduction in Cardiac Scarring and Near-Doubling of Heart Function After Experimental Heart Attack - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/animate-biosciences-reports-preclinical-data-showing-dramatic-reduction-in-cardiac-scarring-and-near-doubling-of-heart-function-after-experimental-heart-attack\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Animate Biosciences Reports Preclinical Data Showing Dramatic Reduction in Cardiac Scarring and Near-Doubling of Heart Function After Experimental Heart Attack - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Single-dose designed peptide drives structural and functional cardiac repair in a mouse myocardial infarction model SAN FRANCISCO–(BUSINESS WIRE)–Animate Biosciences, a biotechnology company focused on designing innovative peptide therapeutics, today announces positive preclinical results demonstrating that its lead therapeutic peptide, MBb32, produced a significant reduction in cardiac scar tissue (infarct) and subsequent recovery of heart function ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/animate-biosciences-reports-preclinical-data-showing-dramatic-reduction-in-cardiac-scarring-and-near-doubling-of-heart-function-after-experimental-heart-attack\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-19T18:06:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260219125573\/en\/2724001\/22\/Animate_Bio_Logo_%284%29.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/animate-biosciences-reports-preclinical-data-showing-dramatic-reduction-in-cardiac-scarring-and-near-doubling-of-heart-function-after-experimental-heart-attack\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/animate-biosciences-reports-preclinical-data-showing-dramatic-reduction-in-cardiac-scarring-and-near-doubling-of-heart-function-after-experimental-heart-attack\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Animate Biosciences Reports Preclinical Data Showing Dramatic Reduction in Cardiac Scarring and Near-Doubling of Heart Function After Experimental Heart Attack\",\"datePublished\":\"2026-02-19T18:06:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/animate-biosciences-reports-preclinical-data-showing-dramatic-reduction-in-cardiac-scarring-and-near-doubling-of-heart-function-after-experimental-heart-attack\\\/\"},\"wordCount\":586,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/animate-biosciences-reports-preclinical-data-showing-dramatic-reduction-in-cardiac-scarring-and-near-doubling-of-heart-function-after-experimental-heart-attack\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260219125573\\\/en\\\/2724001\\\/22\\\/Animate_Bio_Logo_%284%29.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/animate-biosciences-reports-preclinical-data-showing-dramatic-reduction-in-cardiac-scarring-and-near-doubling-of-heart-function-after-experimental-heart-attack\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/animate-biosciences-reports-preclinical-data-showing-dramatic-reduction-in-cardiac-scarring-and-near-doubling-of-heart-function-after-experimental-heart-attack\\\/\",\"name\":\"Animate Biosciences Reports Preclinical Data Showing Dramatic Reduction in Cardiac Scarring and Near-Doubling of Heart Function After Experimental Heart Attack - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/animate-biosciences-reports-preclinical-data-showing-dramatic-reduction-in-cardiac-scarring-and-near-doubling-of-heart-function-after-experimental-heart-attack\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/animate-biosciences-reports-preclinical-data-showing-dramatic-reduction-in-cardiac-scarring-and-near-doubling-of-heart-function-after-experimental-heart-attack\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260219125573\\\/en\\\/2724001\\\/22\\\/Animate_Bio_Logo_%284%29.jpg\",\"datePublished\":\"2026-02-19T18:06:04+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/animate-biosciences-reports-preclinical-data-showing-dramatic-reduction-in-cardiac-scarring-and-near-doubling-of-heart-function-after-experimental-heart-attack\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/animate-biosciences-reports-preclinical-data-showing-dramatic-reduction-in-cardiac-scarring-and-near-doubling-of-heart-function-after-experimental-heart-attack\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/animate-biosciences-reports-preclinical-data-showing-dramatic-reduction-in-cardiac-scarring-and-near-doubling-of-heart-function-after-experimental-heart-attack\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260219125573\\\/en\\\/2724001\\\/22\\\/Animate_Bio_Logo_%284%29.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260219125573\\\/en\\\/2724001\\\/22\\\/Animate_Bio_Logo_%284%29.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/animate-biosciences-reports-preclinical-data-showing-dramatic-reduction-in-cardiac-scarring-and-near-doubling-of-heart-function-after-experimental-heart-attack\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Animate Biosciences Reports Preclinical Data Showing Dramatic Reduction in Cardiac Scarring and Near-Doubling of Heart Function After Experimental Heart Attack\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Animate Biosciences Reports Preclinical Data Showing Dramatic Reduction in Cardiac Scarring and Near-Doubling of Heart Function After Experimental Heart Attack - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/animate-biosciences-reports-preclinical-data-showing-dramatic-reduction-in-cardiac-scarring-and-near-doubling-of-heart-function-after-experimental-heart-attack\/","og_locale":"en_US","og_type":"article","og_title":"Animate Biosciences Reports Preclinical Data Showing Dramatic Reduction in Cardiac Scarring and Near-Doubling of Heart Function After Experimental Heart Attack - Pharma Trend","og_description":"Single-dose designed peptide drives structural and functional cardiac repair in a mouse myocardial infarction model SAN FRANCISCO–(BUSINESS WIRE)–Animate Biosciences, a biotechnology company focused on designing innovative peptide therapeutics, today announces positive preclinical results demonstrating that its lead therapeutic peptide, MBb32, produced a significant reduction in cardiac scar tissue (infarct) and subsequent recovery of heart function ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/animate-biosciences-reports-preclinical-data-showing-dramatic-reduction-in-cardiac-scarring-and-near-doubling-of-heart-function-after-experimental-heart-attack\/","og_site_name":"Pharma Trend","article_published_time":"2026-02-19T18:06:04+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260219125573\/en\/2724001\/22\/Animate_Bio_Logo_%284%29.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/animate-biosciences-reports-preclinical-data-showing-dramatic-reduction-in-cardiac-scarring-and-near-doubling-of-heart-function-after-experimental-heart-attack\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/animate-biosciences-reports-preclinical-data-showing-dramatic-reduction-in-cardiac-scarring-and-near-doubling-of-heart-function-after-experimental-heart-attack\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Animate Biosciences Reports Preclinical Data Showing Dramatic Reduction in Cardiac Scarring and Near-Doubling of Heart Function After Experimental Heart Attack","datePublished":"2026-02-19T18:06:04+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/animate-biosciences-reports-preclinical-data-showing-dramatic-reduction-in-cardiac-scarring-and-near-doubling-of-heart-function-after-experimental-heart-attack\/"},"wordCount":586,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/animate-biosciences-reports-preclinical-data-showing-dramatic-reduction-in-cardiac-scarring-and-near-doubling-of-heart-function-after-experimental-heart-attack\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260219125573\/en\/2724001\/22\/Animate_Bio_Logo_%284%29.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/animate-biosciences-reports-preclinical-data-showing-dramatic-reduction-in-cardiac-scarring-and-near-doubling-of-heart-function-after-experimental-heart-attack\/","url":"https:\/\/pharma-trend.com\/en\/animate-biosciences-reports-preclinical-data-showing-dramatic-reduction-in-cardiac-scarring-and-near-doubling-of-heart-function-after-experimental-heart-attack\/","name":"Animate Biosciences Reports Preclinical Data Showing Dramatic Reduction in Cardiac Scarring and Near-Doubling of Heart Function After Experimental Heart Attack - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/animate-biosciences-reports-preclinical-data-showing-dramatic-reduction-in-cardiac-scarring-and-near-doubling-of-heart-function-after-experimental-heart-attack\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/animate-biosciences-reports-preclinical-data-showing-dramatic-reduction-in-cardiac-scarring-and-near-doubling-of-heart-function-after-experimental-heart-attack\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260219125573\/en\/2724001\/22\/Animate_Bio_Logo_%284%29.jpg","datePublished":"2026-02-19T18:06:04+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/animate-biosciences-reports-preclinical-data-showing-dramatic-reduction-in-cardiac-scarring-and-near-doubling-of-heart-function-after-experimental-heart-attack\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/animate-biosciences-reports-preclinical-data-showing-dramatic-reduction-in-cardiac-scarring-and-near-doubling-of-heart-function-after-experimental-heart-attack\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/animate-biosciences-reports-preclinical-data-showing-dramatic-reduction-in-cardiac-scarring-and-near-doubling-of-heart-function-after-experimental-heart-attack\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260219125573\/en\/2724001\/22\/Animate_Bio_Logo_%284%29.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260219125573\/en\/2724001\/22\/Animate_Bio_Logo_%284%29.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/animate-biosciences-reports-preclinical-data-showing-dramatic-reduction-in-cardiac-scarring-and-near-doubling-of-heart-function-after-experimental-heart-attack\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Animate Biosciences Reports Preclinical Data Showing Dramatic Reduction in Cardiac Scarring and Near-Doubling of Heart Function After Experimental Heart Attack"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62673","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62673"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62673\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62673"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62673"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62673"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}